Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study

Patients with ALK-mutant advanced lung adenocarcinoma have the highest rate of TE. TE is associated with worse survival across molecular subtypes. These findings should be taken into consideration in decision-making regarding thromboprophylaxis. READ ARTICLE

Journal of Thrombosis and Haemostasis DOI:doi.org/10.1111/jth.15215

Authors: Joanna Roopkumar,Shyam K. Poudel,Lorenzo Gervaso,Chandana A. Reddy,Vamsidhar Velcheti,Nathan A. Pennell,Keith R. McCrae,Alok A. Khorana

Real-World OutcomesKirk SmithDecember 14, 2020anaplastic lymphocyte kinase (ALK), epidermal growth factor receptor (EGFR), molecular subtyping, non-small cell lung cancer (NSCLC), thromboembolism

Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung Cancer

Background: Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) can cause intolerable adverse events in patients with non-small cell lung cancer (NSCLC) and may be prescribed at a lower dose. Conclusion: Patients who initiated TKI therapy at a RD did not have different PFS and 15-month survival outcomes than patients who initiated TKI therapy at the FDA SD. READ ARTICLE

Journal of Pharmacy Practice DOI:10.1177/0897190019840596

Authors: Emily Miao, Nagashree Seetharamu, Kevin Sullivan, Stephen Eng, Chung-Shien Lee

Real-World OutcomesKirk SmithJune 5, 2019non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase inhibitor (ALK inhibitor), reduced dose, tyrosine kinase inhibitor (TKI)